Vaxart Q2 FY26 net loss narrows to $13.5 million; revenue falls 31.55% to $27.2 million

Reuters2026/08/06 20:26

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Vaxart posted a Q2 net loss of USD 13.5 million, narrowing from a USD 15 million loss a year earlier; loss per share improved to USD 0.06.
Revenue fell 31.53% to USD 27.2 million, mainly from government contracts, including USD 2.9 million tied to the Dynavax collaboration.
R&D expenses dropped 32.16% to USD 33.7 million, due to lower COVID-19 trial, personnel, facilities, preclinical, and manufacturing costs.
Cash, cash equivalents, and investments totaled USD 64 million at June 30, with runway projected into Q2 2027.
Phase 2b oral COVID-19 pill vaccine sentinel cohort reported no vaccine-related serious adverse events; topline efficacy and safety data for ~5,400 participants due H1 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Vaxart Inc. published the original content used to generate this news brief on August 07, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Vaxart Q2 FY26 net loss narrows to $13.5 million; revenue falls 31.55% to $27.2 million

You may also like

Crypto prices